Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

2014117 citationsJournal Articlegreen Open Access

Authors

Andrew D. Norden · Harvard University Press

Keith L. Ligon

Jan Drappatz · University of Pittsburgh

Abstract

This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months.

Topics & Keywords

Meningioma and schwannoma management Pituitary Gland Disorders and Treatments Neurofibromatosis and Schwannoma Cases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 84, Issue 3, pp. 280-286

DOI: 10.1212/wnl.0000000000001153

Field-Weighted Citation Impact: 3.86